CA3123985A1 - Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound - Google Patents

Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound Download PDF

Info

Publication number
CA3123985A1
CA3123985A1 CA3123985A CA3123985A CA3123985A1 CA 3123985 A1 CA3123985 A1 CA 3123985A1 CA 3123985 A CA3123985 A CA 3123985A CA 3123985 A CA3123985 A CA 3123985A CA 3123985 A1 CA3123985 A1 CA 3123985A1
Authority
CA
Canada
Prior art keywords
sodium
compound
mixture
pharmaceutical composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3123985A
Other languages
English (en)
French (fr)
Inventor
Dong Wang
Qingxia LI
Jun Dai
Chen Li
Zhulian JIANG
Yanqing SUN
Jingjing Chen
Lingling JIN
Jundong LIU
Qide Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CA3123985A1 publication Critical patent/CA3123985A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3123985A 2018-12-24 2019-12-24 Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound Pending CA3123985A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201811581815.8 2018-12-24
CN201811581815 2018-12-24
CN201910679429 2019-07-26
CN201910679429.0 2019-07-26
PCT/CN2019/127837 WO2020135401A1 (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Publications (1)

Publication Number Publication Date
CA3123985A1 true CA3123985A1 (en) 2020-07-02

Family

ID=71126879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3123985A Pending CA3123985A1 (en) 2018-12-24 2019-12-24 Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Country Status (8)

Country Link
US (1) US20220072002A1 (enExample)
EP (1) EP3904356A4 (enExample)
JP (2) JP2022515272A (enExample)
KR (1) KR20210132007A (enExample)
CN (2) CN113242859B (enExample)
AU (1) AU2019413421B9 (enExample)
CA (1) CA3123985A1 (enExample)
WO (1) WO2020135401A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548855A (ja) * 2020-11-05 2023-11-21 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の医薬組成物
CN118973582A (zh) * 2022-03-21 2024-11-15 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2024153148A1 (zh) * 2023-01-18 2024-07-25 北京普祺医药科技股份有限公司 一种杂环化合物、药物组合物及其用途
WO2024230727A1 (zh) * 2023-05-09 2024-11-14 正大天晴药业集团股份有限公司 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775204A1 (en) * 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
US20050130302A1 (en) * 2003-09-29 2005-06-16 Reprocell Inc. Method and composition for regulating expansion of stem cells
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
KR101566840B1 (ko) * 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
AR076794A1 (es) * 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP3354652B1 (en) * 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PH12013502523A1 (en) * 2011-06-14 2019-10-11 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
NZ714502A (en) * 2011-07-05 2017-04-28 Vertex Pharma Processes and intermediates for producing azaindoles
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
CN103585126A (zh) * 2013-11-18 2014-02-19 南京艾德凯腾生物医药有限责任公司 一种托法替尼组合物及制备方法
NZ723859A (en) * 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
AU2015276857B2 (en) * 2014-06-20 2017-10-19 Vaxart, Inc. Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
KR101964546B1 (ko) * 2015-07-27 2019-04-01 유니켐 레버러토리스 리미티드 토파시티닙 경구 붕해 정제
CN108368115B (zh) * 2015-12-15 2020-01-03 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的盐
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN107513067A (zh) * 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
HRP20240112T1 (hr) * 2017-03-14 2024-04-12 Galapagos Nv Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak)
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US12447154B2 (en) * 2020-03-09 2025-10-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome
CA3222218A1 (en) * 2021-06-21 2022-12-29 Lifan TU Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease

Also Published As

Publication number Publication date
US20220072002A1 (en) 2022-03-10
EP3904356A1 (en) 2021-11-03
CN113242859B (zh) 2023-04-14
CN116473973A (zh) 2023-07-25
WO2020135401A1 (zh) 2020-07-02
JP2022515272A (ja) 2022-02-17
AU2019413421B2 (en) 2025-02-13
KR20210132007A (ko) 2021-11-03
JP2025032127A (ja) 2025-03-11
AU2019413421A1 (en) 2021-08-12
AU2019413421B9 (en) 2025-02-20
EP3904356A4 (en) 2022-09-21
CN113242859A (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
AU2019413421B9 (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
US20240423986A1 (en) Treatment of hair loss disorders with deuterated jak inhibitors
US20190269671A1 (en) Method for treating tumour, pharmaceutical composition and medicinal kit
US10485788B2 (en) Pharmaceutical combinations
EP3957631B1 (en) Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma
AU2016213972A1 (en) Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
CN109563088A (zh) MEK/PI3K和mTOR/MEK/PI3K生物途径的多功能抑制剂和使用多功能抑制剂的治疗方法
CN113274392A (zh) 用于治疗慢性咳嗽的奥维匹坦
JPH06234637A (ja) 腫瘍壊死因子アルファを阻害するためのレフルノミドの使用
KR20080081358A (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
CN104844600A (zh) 一种他达拉非化合物、及其组合物
JP2012526089A (ja) カバジタキセルおよびカペシタビンを含む抗腫瘍性組み合わせ
EP1655029B1 (en) Medicinal compositions
RU2810112C2 (ru) Лечебное применение пирролопиримидинового соединения и твердая фармацевтическая композиция пирролопиримидинового соединения
HK40063616A (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
HK40055927B (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
HK40055927A (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
CN120676939A (zh) Pi3k抑制剂及其制备和使用方法
US20190040073A1 (en) Nonanoic and decanoic acid derivatives and uses thereof
TW202245780A (zh) 用於治療神經膠質母細胞瘤之方法
WO2022268075A1 (zh) 化合物在制备用于治疗骨髓纤维化及其相关症状/体征的药物中的应用、该化合物的用途
TW202245786A (zh) 喹唑啉化合物及藥物組合物的應用
JP2015067565A (ja) ３−（１５−ヒドロキシペンタデシル）−２，４，４−トリメチル−２−シクロヘキセン−１−オン又はその塩を含有する医薬組成物
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231108

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250314

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250318

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260331

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260331